Ideas & Impact › Resources › Global Fund Allocation Process Overview

This brief outlines the allocation process for the Global Fund to Fight AIDS, Tuberculosis, and Malaria, which can be used by implementing partners to procure funding. It includes a checklist and messages to ensure children, adolescents, & youth are prioritized in Global Fund proposals

Explore Related Resources

Search More Resources

Journal Articles

Tuberculosis Preventive Treatment Uptake Among Patients Initiating Antiretroviral Therapy in Malawi: Children Left Behind

Published November 2025

Background: Tuberculosis preventive treatment (TPT) is recommended for people living with HIV (PLHIV) to reduce the tuberculosis (TB) incidence in regions with a high prevalence of TB. We evaluated the uptake and completion of TPT among newly initiated antiretroviral therapy (ART) patients in a programme setting in Malawi. Objectives: To describe TPT initiation and completion rates, and […]

Topics:

Pediatric Tuberculosis (TB),

Tuberculosis (TB)

Countries:

Malawi

Project Brief

Integrating Nurturing Care for Early Childhood Development into Primary Health Care: The Tanzania Experience

Published July 2025

Overview More than 275 million children in low- and middle-income countries are at risk of suboptimal development, including over 66% of children in sub-Saharan Africa. In Tanzania 43% of children are at high risk of not achieving their full potential for growth and development. Risk factors for suboptimal development include poverty, nutritional deficiencies, maternal depression, […]

Countries:

Tanzania

Journal Articles

Accelerating Access to Paediatric Medicines

Published April 2025

Overview Despite progress in reducing neonatal and child mortality, access to age-appropriate medicines remains inequitable, particularly in low-income and middle-income countries. The Global Accelerator for Paediatric Formulations (GAP-f), a WHO-hosted network established in 2020, addresses these gaps by uniting 33 partners to promote innovation and access to child-friendly formulations. Phase 2 (2022–24) of GAP-f’s work […]